Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial von Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

Volltext

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–... von BARLESI, Fabrice, SCHERPEREEL, Arnaud, WONG, Elaine K, PEREZ-MORENO, Pablo, MITCHELL, Lada, GROEN, Harry J. M, RITTMEYER, Achim, PAZZOLA, Antonio, FERRER TUR, Neus, KIM, Joo-Hang, AHN, Myung-Ju, AERTS, Joachim G. J. V, GORBUNOVA, Vera, VIKSTRÖM, Anders

Volltext

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics von Claret, Laurent, Jin, Jin Y, Ferté, Charles, Winter, Helen, Girish, Sandhya, Stroh, Mark, He, Pei, Ballinger, Marcus, Sandler, Alan, Joshi, Amita, Rittmeyer, Achim, Gandara, David, Soria, Jean-Charles, Bruno, René

Volltext

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study von Gandara, David R., von Pawel, Joachim, Mazieres, Julien, Sullivan, Richard, Helland, Åslaug, Han, Ji-Youn, Ponce Aix, Santiago, Rittmeyer, Achim, Barlesi, Fabrice, Kubo, Toshio, Park, Keunchil, Goldschmidt, Jerome, Gandhi, Mayank, Yun, Cindy, Yu, Wei, Matheny, Christina, He, Pei, Sandler, Alan, Ballinger, Marcus, Fehrenbacher, Louis

Volltext

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-... von Griesinger, Frank, Eberhardt, Wilfried, Nusch, Arnd, Reiser, Marcel, Zahn, Mark-Oliver, Maintz, Christoph, Bernhardt, Christiane, Losem, Christoph, Stenzinger, Albrecht, Heukamp, Lukas C., Büttner, Reinhard, Marschner, Norbert, Jänicke, Martina, Fleitz, Annette, Spring, Lisa, Sahlmann, Jörg, Karatas, Aysun, Hipper, Annette, Weichert, Wilko, Heilmann, Monika, Sadjadian, Parvis, Gleiber, Wolfgang, Grah, Christian, Waller, Cornelius F., Reck, Martin, Rittmeyer, Achim, Christopoulos, Petros, Sebastian, Martin, Thomas, Michael

Volltext

Update on recent key publications in lung oncology: picking up speed von Rittmeyer, Achim, Schiwitza, Annett, Sahovic, Lejla, Eul, Bastian, Andreas, Stefan

Volltext

Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients von Reinhardt, Christian, Harden, Markus, Herrmann-Lingen, Christoph, Rittmeyer, Achim, Andreas, Stefan

Volltext

Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stag... von Brueckl, Wolfgang M, Reck, Martin, Rittmeyer, Achim, Kollmeier, Jens, Wesseler, Claas, Wiest, Gunther H, Christopoulos, Petros, Tufman, Amanda, Hoffknecht, Petra, Ulm, Bernhard, Reich, Fabian, Ficker, Joachim H, Laack, Eckart

Volltext

Treatment of limited disease small cell lung cancer: the multidisciplinary team von Glatzer, Markus, Rittmeyer, Achim, Müller, Joachim, Opitz, Isabelle, Papachristofilou, Alexandros, Psallidas, Ioannis, Früh, Martin, Born, Diana, Putora, Paul Martin

Volltext

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial von Gadgeel, Shirish, Hirsch, Fred R., Kerr, Keith, Barlesi, Fabrice, Park, Keunchil, Rittmeyer, Achim, Zou, Wei, Bhatia, Namrata, Koeppen, Hartmut, Paul, Sarah M., Shames, David, Yi, Jing, Matheny, Christina, Ballinger, Marcus, McCleland, Mark, Gandara, David R.

Volltext

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel von Gandara, David, Reck, Martin, Moro-Sibilot, Denis, Mazieres, Julien, Gadgeel, Shirish, Morris, Stefanie, Cardona, Andres, Mendus, Diana, Ballinger, Marcus, Rittmeyer, Achim, Peters, Solange

Volltext

Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy von Iseli, Thomas, Berghmans, Thierry, Glatzer, Markus, Rittmeyer, Achim, Massard, Gilbert, Durieux, Valerie, Buchsbaum, Thomas, Putora, Paul Martin

Volltext

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) von Spira, Alexander I., Park, Keunchil, Mazières, Julien, Vansteenkiste, Johan F., Rittmeyer, Achim, Ballinger, Marcus, Waterkamp, Daniel, Kowanetz, Marcin, Mokatrin, Ahmad, Fehrenbacher, Louis

Volltext

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lu... von West, Howard, McCleod, Michael, Hussein, Maen, Morabito, Alessandro, Rittmeyer, Achim, Conter, Henry J, Kopp, Hans-Georg, Daniel, Davey, McCune, Steven, Mekhail, Tarek, Zer, Alona, Reinmuth, Niels, Sadiq, Ahad, Sandler, Alan, Lin, Wei, Ochi Lohmann, Tania, Archer, Venice, Wang, Lijia, Kowanetz, Marcin, Cappuzzo, Federico

Volltext

Quality of Life in Patients with NSCLC Receiving Maintenance Therapy von Rittmeyer, Achim

Volltext

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab von Gandara, David R., Paul, Sarah M., Kowanetz, Marcin, Schleifman, Erica, Zou, Wei, Li, Yan, Rittmeyer, Achim, Fehrenbacher, Louis, Otto, Geoff, Malboeuf, Christine, Lieber, Daniel S., Lipson, Doron, Silterra, Jacob, Amler, Lukas, Riehl, Todd, Cummings, Craig A., Hegde, Priti S., Sandler, Alan, Ballinger, Marcus, Fabrizio, David, Mok, Tony, Shames, David S.

Volltext

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer von Wu, Yi-Long, Tsuboi, Masahiro, He, Jie, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W, Laktionov, Konstantin, Kim, Sang-We, Kato, Terufumi, Vu, Huu-Vinh, Lu, Shun, Lee, Kye-Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A, Zeng, Lingmin, Hodge, Rachel, Atasoy, Ajlan, Rukazenkov, Yuri, Herbst, Roy S

Volltext

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials von Mazieres, Julien, Rittmeyer, Achim, Gadgeel, Shirish, Hida, Toyoaki, Gandara, David R., Cortinovis, Diego L., Barlesi, Fabrice, Yu, Wei, Matheny, Christina, Ballinger, Marcus, Park, Keunchil

Volltext

Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (O... von Rittmeyer, Achim, Scherpereel, Arnaud, Gorbunova, Vera A., Gervais, Radj, Vikström, Anders, Chouaid, Christos, Chella, Antonio, Kim, Joo-Hang, Ahn, Myung-Ju, Reck, Martin, Pazzola, Antonio, Kim, Heung Tae, Aerts, Joachim, Groen, Harry J.M., Morando, Claire, Loundou, Anderson, Barlesi, Fabrice

Volltext

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers von Peters, Solange, Stahel, Rolf, Bubendorf, Lukas, Bonomi, Philip, Villegas, Augusto, Kowalski, Dariusz M, Baik, Christina S, Isla, Dolores, Carpeno, Javier De Castro, Garrido, Pilar, Rittmeyer, Achim, Tiseo, Marcello, Meyenberg, Christoph, de Haas, Sanne, Lam, Lisa H, Lu, Michael W, Stinchcombe, Thomas E

Volltext